HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lack Of Supplement NDI Notification Guidance Not A Market Pass For Industry

This article was originally published in The Rose Sheet

Executive Summary

Manufacturers, ingredient suppliers and other parties submitting NDI notifications can improve the industry's outlook by "anticipating future products that haven't been brought to market yet" and proposing the highest concentration of an ingredient for the broadest variety of uses, says ODSP senior advisory Cara Welch.

You may also be interested in...



NAC’s Longevity In US Dietary Supplement Market Swings On Comments As NDI Notifications

FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.

US FDA Struggling To Regulate Supplement Industry – Former Agency Chief Counsel

Stacy Cline Amin expects publication in “near future” of draft guidance on FDA’s NDI notification requirement, a document the agency says it expects to provide within a year. Amin, now with Morrison & Foerster as partner in Washington, also acknowledged FDA’s predicament with regulating products containing cannabinoids.

Drug Innovation Needs Exclusivity For Some Natural Substances, PhRMA Recommends

In comments on VMS industry oversight, PhRMA recommends FDA adhere to clear regulations that determine whether substances are eligible for use as dietary ingredients. DSHEA makes clear that some dietary ingredients are not eligible for use VMS products.

Related Content

Topics

UsernamePublicRestriction

Register

RS109339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel